Avaxia is a clinical-stage biotechnology company focused on gut-targeted antibody therapeutics for gastroenterology diseases. Gut-targeted antibody therapeutics are orally administered, minimally absorbed drugs that act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. In contrast, conventional antibody therapeutics are injected or infused into the bloodstream and distribute throughout the body. Avaxia believes that local treatment of GI diseases at their source with gut-targeted antibodies has the potential to minimize side effects that often occur with parenteral antibodies. Avaxia intends to develop and market our drugs for orphan diseases, especially pediatric indications, while partnering for the larger adult market.